- Home
- TRX vs TLSI Comparison
TRX vs TLSI Comparison
Compare TRX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRX | TLSI |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.9M | 244.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TRX | TLSI |
|---|---|---|
| Price | $0.86 | $7.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.25 | ★ $10.67 |
| AVG Volume (30 Days) | ★ 1.4M | 175.5K |
| Earning Date | 01-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $57,613,000.00 | $40,207,000.00 |
| Revenue This Year | $28.16 | $55.06 |
| Revenue Next Year | N/A | $46.04 |
| P/E Ratio | $363.98 | ★ N/A |
| Revenue Growth | 39.98 | ★ 49.52 |
| 52 Week Low | $0.27 | $3.42 |
| 52 Week High | $0.89 | $7.70 |
Technical Indicators
Market Signals| Indicator | TRX | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 68.56 | 69.33 |
| Support Level | $0.70 | $6.06 |
| Resistance Level | $0.89 | $7.70 |
| Average True Range (ATR) | 0.05 | 0.63 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 89.31 | 84.65 |
Price Performance
Historical ComparisonAbout TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.